Bayer announced that the company has closed the previously announced transaction with Ginkgo Bioworks to begin a multi-year strategic partnership to accelerate research and development of biological products for agriculture.
Ginkgo to acquire Bayer's 175,000-square-foot Biologics RD center and enter into a new multi-year platform collaboration with Bayer to advance several agricultural biological programs SOURCE: Bayer DESCRIPTION:BOSTON, July 27, 2022 /3BLMedia/ - Ginkgo Bioworks (NYSE: DNA), the leading horizontal platform for cell programming, announced the signing of a definitive agreement for the previously announced transaction with Bayer to expand Ginkgo's platform capabilities in agricultural biologicals. The
Bayer announced that the company is pursuing an agreement whereby Ginkgo Bioworks will acquire Bayer’s West Sacramento Biologics Research & Development (R&D) site and internal discovery and lead optimization platform.
Quest Diagnostics recently announced it has formed an agreement with the Texas Department of State Health Services to provide COVID-19 K-12 school testing services to support safer classroom learning throughout the state of Texas.